COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Articles on Pharmaceutical companies
Displaying 21 - 30 of 30 articles
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A private market should have no place in the rollout of a COVID vaccine.
Drug companies normally use patents to protect new treatments.
Previously secret documents and data make it clear that many companies engaged in the distribution of prescription painkillers either skirted or ignored their legal obligations for years.
The first study to assess the carbon footprint of the pharmaceutical industry finds that it is far from green.
The interests of pharmaceutical companies and public health are not the same. Industry dollars can distort research agendas, while framing health challenges and solutions in ways that benefit corporations.
It takes about three years for safety problems to be identified in new drugs, newer drugs are almost always more expensive, and yet Canadian doctors still hand out hundreds of thousands of samples.
The end of effective antibiotics will be frightening. Life expectancy will fall dramatically and people of all ages will die from illnesses that we are used to treating with $10 worth of pills.
Nevada plans to use a new drug protocol for executing Scott Dozier, who murdered a 22-year-old. A scholar explains why this is problematic.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor of Philosophy, Binghamton University, State University of New York
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Lecturer, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Professeur des Universités, IAE Paris – Sorbonne Business School
-
Chen Su Lan Centennial Professor in Medical Ethics, National University of Singapore; Distinguished Visiting Professor in Law, University of Melbourne; Uehiro Chair in Practical Ethics, The University of Melbourne
-
Professor of Biochemistry and Biomedical Sciences, McMaster University
-
Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
-
Associate Professor of History, Florida International University
-
Professor of Intellectual Property Law, City St George's, University of London
-
Adjunct Lecturer, School of Pharmacy, University of Sydney
-
Henry Baldwin Professorial Research Fellow in Health System Sustainability, University of Tasmania